dr. levy discusses pembrolizumab in nsclc
Published 6 years ago • 147 plays • Length 1:50Download video MP4
Download video MP3
Similar videos
-
1:56
dr. levy on impact of nivolumab, pembrolizumab approvals in nsclc
-
1:14
dr. levy on investigational biomarkers of response to immunotherapy in nsclc
-
5:00
implications for pembrolizumab in nsclc
-
1:50
dr. levy on therapy for rapidly progressing nsclc
-
4:05
pembrolizumab chemotherapy in newly diagnosed nsclc
-
1:50
dr. levy discusses the flaura study in lung cancer
-
1:09
dr. levy on first-line treatment for nondriver nsclc
-
1:03
dr. rizvi discusses pembrolizumab for non-small cell lung cancer
-
1:16
dr. levy on treatments for oncogenic-driven nsclc
-
1:19
benjamin philip levy, md, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab
-
1:16
dr. levy on positive and negative biomarkers for immunotherapy in lung cancer
-
5:54
pembrolizumab in newly diagnosed squamous nsclc
-
1:02
dr. levy discusses the outlook for oncogene-driven nsclc
-
1:22
dr. levy on the benefits of liquid biopsies in nsclc
-
6:21
lung cancer video library 2020 - levy - immunotherapy in patients with driver mutations
-
2:04
dr. levy on biomarkers of response to immunotherapy
-
7:54
lung cancer video library 2020 - levy - immunotherapy combinations for advanced nsclc
-
1:48
dr. brahmer discusses frontline single-agent pembrolizumab in lung cancer
-
2:12
dr. mok discusses updated data with pembrolizumab in nsclc